Avacta Group, a UK-based healthcare technology and consumables business, has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space.

The move, which follows the recent acquisition of affinity reagents specialist Aptuscan, brings together the entire Avacta Group on the same site.

The new facilities, which include purpose built laboratories, are at Avacta's existing Thorp Arch Estate premises in Wetherby, UK, and have been taken on to accommodate the Company's current rapid expansion. Alastair Smith, Chief Executive of Avacta, commented: "Our core businesses are seeing strong growth, and recent funding, together with the acquisition of Aptuscan, will ensure we are able to accelerate our existing product development pipeline. Thorp Arch Estate is an ideal location for biotechnology enterprises, with excellent transport connections, and we are enthusiastic about plans to create a wider science park facility here." 

For more information, visit www.avactaanalytical.com
 

About Avacta Analytical

Avacta Analytical provides services and innovative instrumentation to the biopharmaceutical market. Our focus is to equip customers with a broad range of capabilities, enabling them to develop their therapeutics quicker, cheaper and better.

The groundbreaking Optim 1000 is an innovative analytical instrument designed to probe multiple stability-indicating parameters at high speed using ultra-low sample volumes of proteins and other molecules.

Our services business specialises in supporting characterisation, formulation, comparability and stability studies of therapeutic proteins. We are able to draw upon a wide range of analytical capabilities and aim to give our customers a flexible value-added service.

Avacta Analytical is an ISO 9001 2008 registered company.